Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claims about ENHERTU’s ILD/pneumonitis risk and embryo-fetal toxicity are directly supported by the provided FDA label excerpts (Boxed Warning, Warnings and Precautions 5.1/5.4, and Dose Modifications 2.3, plus pregnancy/reproductive population sections 8.1 and 8.3). No contradictions or unsupported warning content were identified.
Category Scores
Accurate Statements
ENHERTU has a Boxed Warning for interstitial lung disease (ILD) and pneumonitis, including severe, life-threatening, and fatal cases, and recommends monitoring for respiratory symptoms and promptly investigating them.
Boxed Warning (ILD and pneumonitis portion): reports ILD/pneumonitis (severe/life-threatening/fatal); monitor and promptly investigate signs/symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms.
For symptomatic ILD (Grade 2 or greater), ENHERTU should be permanently discontinued and systemic corticosteroids should be promptly initiated.
Section 2.3 (Dosage Modifications for Adverse Reactions) / Table 3: Symptomatic ILD/pneumonitis (Grade 2 or greater): permanently discontinue ENHERTU; promptly initiate corticosteroids. Also aligns with Section 5.1 management language.
Section 5.1 states severe, life-threatening, or fatal ILD (including pneumonitis) can occur and includes monitoring/evaluation and corticosteroid initiation with permanent discontinuation for symptomatic (Grade 2 or greater) ILD.
Section 5.1 (Interstitial Lung Disease/Pneumonitis): severe/life-threatening/fatal ILD can occur; advise reporting symptoms and monitor; promptly investigate; symptomatic (Grade 2 or greater): initiate systemic corticosteroids and permanently discontinue ENHERTU.
ENHERTU has a Boxed Warning for embryo-fetal toxicity; exposure during pregnancy can cause embryo-fetal harm.
Boxed Warning (Embryo-Fetal Toxicity portion): exposure during pregnancy can cause embryo-fetal harm; advise patients and effective contraception; cites 5.4 and 8.3.
Section 5.4 describes embryo-fetal toxicity risk based on ENHERTU’s mechanism of action, advises counseling about fetal risks, and provides contraception and pregnancy-verification guidance.
Section 5.4 (Embryo-Fetal Toxicity): can cause fetal harm; advises patients of potential risks; verify pregnancy status; advise effective contraception for females of reproductive potential during treatment and for 7 months after last dose; and for males with female partners for 4 months after last dose (with reproductive timing also referenced elsewhere).
Sections 8.1 and 8.3 address pregnancy risk and reproductive contraception/timeframes (including monitoring for oligohydramnios and contraception duration after last dose).
Section 8.1 (Pregnancy): advises potential fetal risks and monitoring women for oligohydramnios after exposure. Section 8.3 (Females and Males of Reproductive Potential): verify pregnancy status; effective contraception for females during treatment and for 7 months after last dose; males with female partners effective contraception during treatment and for 4 months after last dose.
Unsupported Statements
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No material omissions were identified for the specific warning topics evaluated (ILD/pneumonitis and embryo-fetal toxicity).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated warning/counseling elements correspond to label-supported requirements (monitoring/evaluation and permanent discontinuation for Grade ≥2 symptomatic ILD; pregnancy/contraception and embryo-fetal harm counseling). No contradictory or unsupported safety claims were identified from the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement